The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis

Thrombosis and Haemostasis

Volumn 78, Issue 4, 1997, Pages 1286-1292

  Elg, Margareta ^a   Gustafsson, David ^a   Deinum, Johanna ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EFEGATRAN; FERRIC CHLORIDE; HEPARIN; HIRUDIN; INOGATRAN; LEPIRUDIN; THROMBIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; CAROTID ARTERY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; ENZYME INHIBITION; INHIBITION KINETICS; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030707669     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657729     Document Type: Article

References (33)

1. Badimon L, Meyer BJ, Badimon JJ. Thrombin in arterial thrombosis. Haemostasis 1994; 24 (2): 69-80.
2. Bloom AL. Physiology of blood coagulation. Haemostasis 1990; 20 (Suppl 1): 14-29.
3. Stone SR, Tapparelli C. Thrombin inhibitors as antithrombotic agents: the importance of rapid inhibition. J Enzym Inhib 1995; 9 (1): 3-15.
4. Kettner C, Mersinger L, Knabb R. The selective inhibition of thrombin by peptides of boroarginine. J Biol Chem 1990; 265 (30): 18289-97.
5. Nilsson T, Sjöling-Ericksson Å, Deinum J. The mechanism of binding of low-molecular weight active site inhibitors to human alpha-thrombin. Biochem J, submitted.
6. Römisch J, Diehl KH, Hoffmann D, Krahl-Mateblowski U, Reers M, Stüber W, Pâques EP. Comparison of in vitro and in vivo properties of r-hirudin (HBW 023) and a synthetic analogous peptide. Haemostasis 1993; 23 (5): 249-58.
7. Bridey F, Dreyfus M, Parent F, Bros A, Fisher AM, Camez A, Simonneau G, Duroux P, Meyer D. Recombinant hirudin (HBW 023): biological data of ten patients with severe venous thrombo-embolism. Am J Hematol 1995; 49 (1): 67-72.
8. Teger-Nilsson A, Bylund R, Gustafsson D, Gyzander E, Eriksson U. In vitro effects of inogatran, a selective LMW thrombin inhibitor. Thromb Haemost 1997; in press.
9. Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I, Elg M, Mattsson C, Deinum J, Pehrsson S, Karlsson O, Nilsson A, Sörensen H. Effects of melagatran, a new low molecular weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost (To be published).
10. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res 1994; 74 (1): 1-23.
11. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29 (30): 7095-101.
12. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association. Circulation 1994; 89 (3): 1449-68.
13. Bush LR. Argatroban, a selective, potent thrombin inhibitor. Cardiovascular Drug Reviews 1991; 9 (3): 247-63.
14. 2Cl-A selective affinity label for thrombin. Thromb Res 1979; 14 (6): 969-73.
15. Atrash B, Jones D, Szelke M. European Patent Application 0530167A.
16. Bajusz S. Chemistry and biology of the peptide anticoagulant D-MePhe-Pro-Arg-H (GYKI-14766). Adv Exp Med Biol 1993; 340: 91-108.
17. Kikumoto R, Tamao Y, Tezuka T, Tonomura S. Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl++ +) sulfonyl]-l-arginyl)]-2-piperidinecarboxylic acid. Biochemistry 1984; 23 (1): 85-90.
18. Teger-Nilsson A, Bylund R. Preparation of peptide derivates as thrombin inhibitors. Patent Application WO9311152-A1.
19. Antonsson T, Bylund R, Gustafsson D, Nilsson I. New peptide derivatives. Patent Application WO9429336-A.
20. Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990; 60 (4): 269-80.
21. Davies MJ, Thomas AC. Plaque fissuring-the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53 (4): 363-73.
22. Gustafsson D, Elg M, Lenfors S, Börjesson I, Teger-Nilsson AC. Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time. Blood Coagul Fibrinolysis 1996; 7 (1): 69-79.
23. Challapalli R, Lefkovits J, Topol EJ. Clinical trials of recombinant hirudin in acute coronary syndromes. Coron Artery Dis 1996; 7: 429-37.
24. Parry MA, Maraganore JM, Stone SR. Kinetic mechanism for the interaction of Hirulog with thrombin. Biochemistry 1994; 33 (49): 14807-14.
25. Witting JI, Bourdon P, Brezniak DV, Maraganore JM, Fenton JWd. Thrombin-specific inhibition by and slow cleavage of hirulog-1 [see comments]. Biochemical J 1992; 283 (Pt 3): 737-43.
26. Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci USA 1989; 86 (10): 3619-23.
27. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86 (2): 385-91.
28. May RD, Hawkeswood E, Powling MJ. British Society for Haemostasis and Thrombosis. London, 12 September 1994. Abstracts. Blood Coagul Fibrinolysis 1994; 5 (5): 812.
29. Gast A, Tschopp TB, Schmid G, Hilpert K, Ackermann J. Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma. Blood Coagul Fibrinolysis 1994; 5 (6): 879-87.
30. Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin. Thromb Haemost 1994; 72 (3): 381-6.
31. Bendayan P, Boccalon H, Dupouy D, Boneu B. Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins. Thromb Haemost 1994; 71 (5): 576-80.
32. Tapparelli C, Metternich R, Ehrhardt C, Zurini M. In vitro and in vivo characterization of a neutral boron-containing thrombin inhibitor. J Biol Chem 1993; 268 (7): 4734-41.
33. Jackman MP, Parry MA, Hofsteenge J, Stone SR. Intrinsic fluorescence changes and rapid kinetics of the reaction of thrombin with hirudin. J Biol Chem 1992; 267 (22): 15375-83.